Academy Sports and Outdoors: Improved Sales, Persistent Traffic Challenges
Finance

Academy Sports and Outdoors: Improved Sales, Persistent Traffic Challenges

authorBy Nouriel Roubini
DateJul 10, 2026
Read time2 min

Academy Sports and Outdoors (ASO) has received a 'Hold' rating due to an ongoing challenge with customer traffic, despite experiencing an increase in demand and overall sales. While digital initiatives, loyalty programs, and new store openings are seen as beneficial developments, the core issue of declining foot traffic persists. The company's future growth strategy is heavily focused on expanding its physical footprint and enhancing its myAcademy Rewards loyalty program to attract more customers and encourage repeat business.

Management's outlook for fiscal year 2026 projects sales to be in the range of $6.23 billion to $6.355 billion, with an anticipated adjusted earnings per share (EPS) of $6.40 to $6.80. This forecast suggests a robust EPS growth of 11% to 18%. The company's current valuation, at approximately 6.7 times next twelve months' price-to-earnings (NTM PE), appears undemanding. However, for a more optimistic re-rating from investors, there needs to be clearer evidence of sustained transaction growth and improved clarity on profit margins.

Ultimately, Academy Sports and Outdoors possesses a solid foundation and clear strategies for future expansion. Overcoming the challenge of negative transaction growth will be crucial for the company to fully capitalize on its new initiatives and achieve its ambitious financial targets. A sustained upward trajectory in customer engagement and streamlined operational efficiency will undoubtedly pave the way for long-term success and a more favorable market perception.

More Articles
Finance
AT&T: Options Traders in Panic, a Sell Opportunity?
Amidst broader market corrections and industry shifts, AT&T's implied volatility has surged to the 99th percentile, indicating market overreaction. This creates a compelling chance for short-term option selling. While long-term concerns exist due to market changes, AT&T's current valuation and strategic initiatives offer substantial mitigation.
By David RubensteinJul 10, 2026
Finance
Geopolitical Risks and Market Sentiment: An Analysis of Oil Prices and Interest Rates
This article examines how geopolitical events, specifically rising oil prices, are influencing global financial markets. It delves into the interplay between oil prices, inflation expectations, and nominal interest rates, while also assessing the seemingly detached optimism in risk assets. The analysis further explores the potential implications of Japanese pension funds shifting towards domestic investments on European government bonds, particularly impacting France.
By Nouriel RoubiniJul 10, 2026
Finance
Calamos Market Neutral Income Fund: Steady Performance in a Volatile Bond Market
The Calamos Market Neutral Income Fund (CMNIX) is designed to provide stable returns regardless of interest rate fluctuations. The fund has consistently outperformed the broader bond market over various periods, including the most recent quarter and year-to-date. Its success is attributed to core strategies like convertible arbitrage and hedged equity, alongside allocations to merger arbitrage and SPAC arbitrage, all of which contributed positively to its performance.
By Strive MasiyiwaJul 10, 2026
Finance
The Role of AI in Retirement Planning: Benefits and Limitations
Artificial intelligence tools like ChatGPT can provide valuable insights for retirement planning, answering questions on topics such as Social Security and tax minimization. However, financial experts emphasize that AI lacks critical thinking and cannot replace the personalized guidance of a human financial advisor. While AI can help familiarize individuals with financial concepts and research, it's crucial to verify its sources and not solely rely on it for complex financial decisions, especially given potential data privacy risks.
By Mariana MazzucatoJul 10, 2026
Finance
Palisade Bio: Pioneering Ulcerative Colitis and Crohn's Treatment
Palisade Bio, a biotechnology firm, is advancing PALI-2108 for Ulcerative Colitis and Crohn's disease. This novel PDE4 inhibitor prodrug has shown promise in Phase 1 trials, demonstrating safety, target engagement, and early clinical efficacy. With substantial funding, the company is poised for upcoming Phase 2 readouts, potentially mirroring the success of other oral UC therapies in the market.
By Morgan HouselJul 10, 2026